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Abstract. The importance of (thio)urea organocatalysts for the efficient construction of N-, O- and S-
heterocyclic compounds is briefly disclosed. Thus, in this chapter, representative examples where the 
heterocyclic ring is formed in the course of the reactions promoted by those chiral catalysts are covered. 
This compilation excludes examples where there is no new heterocyclic moiety in the final product, with 
respect to the starting compounds. The use of these methodologies allows the obtainment of a wide variety 
of heterocyclic structures, such as tetrahydro-β-carbolines, 1,4-dihydropyridines, indolines, pyrrolidines, 2-
amino-4H-chromene derivatives, flavanones, chromanones, pyrans, tetrahydrofurans and benzothiopyrans. 
This kind of structures is present in natural products and biologically active compounds, being of great 
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In the last years, catalysts acting through hydrogen bonds have fascinated the scientists, becoming the 
center of research of many groups. This kind of activation represents a significant part of the organocatalysis 
field.1 Among the different types of hydrogen bond based catalysts, chiral thiourea/urea derivatives are of 
great interest and have been focus of intensive studies, resulting to be appropriated catalysts in numerous 
pivotal processes.2 In this context, we have centered part of our investigation on the employment of chiral 
(thio)urea for the development of new organocatalyzed asymmetric methods.3 
 
 
Many of these model thioureas represented in Figure 1, have inspired further investigations and more 









We want to disclose here the importance of thiourea organocatalysts for the efficient construction of 
heterocyclic compounds. In this chapter, we will cover representative examples where the heterocyclic ring 
is formed in the course of the reactions. We have selected some pivotal heterocyclic rings which are core 
structural motifs in many natural products and biologically active compounds (Figure 2). Many other 
examples that do not appear in this chapter have also successfully contributed to the expansion of 
Heterocyclic Chemistry. 
 
2. Synthesis of N-heterocyclic compounds 
2.1. Synthesis of tetrahydro-β-carbolines 
Tetrahydro-β-carboline rings are present in many natural and synthetic organic compounds possessing 
a wide diversity of important biological activities (Figure 3).5 Pictet-Spengler reaction represents a well-
established synthetic approach for the preparation of these systems.6 In the last decade, the enantioselective 









In this field, Jacobsen and co-workers pioneered in 2004 a thiourea catalyzed example of an acyl-
Pictet-Spengler reaction, providing access to different N-acetyl β-carbolines 2 in high enantioselectivies (85-
95%) and moderate yields (65-81%) (Scheme 1).7,8 The authors envisioned the possibility of activating this 
procedure using thiourea catalysts based in the acyl-Pictet-Spengler reaction mechanism (Scheme 2) and in 





2.2. Synthesis of 1,4-dihydropyridines 
1,4-Dihydropyridines (1,4-DHP) and their derivatives are important building blocks and versatile 
synthons in Organic Synthesis owing their biological and broad range of pharmacological properties (Figure 
4).9 However, their enantioselective synthesis has been less explored and the development of new chiral 





Takemoto’s group has developed an interesting synthesis of functionalized 1,4-DHP 5 following a 
Brønsted acid–thiourea co-catalyzed asymmetric cycloaddition of β-enamino esters 3 and α,β-unsaturated 
aldehydes 4 using novel thiourea catalyst II (Scheme 3).10 The authors proposed the mechanism depicted in 






































The ammonium salt complex A is formed from a mixture of thiourea II and a Brønsted acid (HX) 
(1:1) and it is the new bifunctional catalyst. Thus, enamino ester 3 and α,β-unsaturated aldehyde 4 should be 
activated by the ammonium proton and the conjugate base (X–), respectively, leading to the corresponding 
Michael product 6. The desired 1,4-DHP 5 is obtained after subsequent intramolecular cyclization and 
dehydration of 6. The merit of this strategy is that the acidity and basicity of complex A can be tuned by 
appropriate selection of the acid (HX). 
 
2.3. Synthesis of indolines 
The indole core and its derivatives are privilege structural motifs present in many natural products and 
the construction of this skeleton is nowadays an active area of research in Organic Synthesis.11 Special 
interest has received the preparation of chiral scaffolds bearing this core through metal- and organo-
catalysis.12 An important type of molecules belonging to this family is the indoline, which also exhibits 








































In this field, Asano, Matsumara and co-workers developed a new method for the asymmetric synthesis 
of 2-substituted indolines 8, employing bifunctional aminourea IIIa as catalyst and α,β-unsaturated 
carboxylic acid derivatives 7 as starting material (Scheme 5). Final indolines 8 were obtained in moderate to 
good yields (24-99%) and with high enantioselectivities (74-93%).14 
The reaction is supposed to proceed via an intramolecular aza-Michael addition mediated by hydrogen 
bond interactions, although the authors did not propose any tentative activation mechanism. The catalytic 
 
 
process was highly versatile and applicable to a wide range of α,β-unsaturated carboxylic acid derivatives 7, 





2.4. Synthesis of pyrrolidines 
Pyrrolidines are common cores in many natural products and pharmacologically active scaffolds, such 
as L-proline,15 (–)-kainic acid,16 swainsone,17 (–)-mesembrine,18 (–)-slaframine,19 and lepadiformine20 
(Figure 6).21 Many efforts have been devoted to the enantioselective synthesis of these functionalized 






Zhang and co-workers reported the first asymmetric 1,3-dipolar cycloaddition of azomethineylides23 
12 with nitroalkenes 10 for the preparation of highly functionalized pyrrolidines 11 in good yields (49-77%), 
high diastereoselectivities (up to >99:1) and moderate enantioselectivities (46-65%) (Scheme 6).24 
The authors envisioned that the enolate 12, which can be formed by treatment of 9 with a Lewis 
base, would attack the nitroalkenes 10, activated at the same time through hydrogen-bonds between the nitro 
 
 
group of 10 and the NH protons of the thiourea catalyst IV (complex A), favoring the subsequent apparent 





Contemporaneously, Takemoto’s group reported a similar 1,3-dipolar cycloaddition process catalyzed 
by chiral thiourea V (Scheme 7).25 The authors proposed that the possible stepwise mechanism could 
proceed via a first Michael addition and a successive intramolecular aza-Henry reaction, as depicted in 





In this mechanism, the formal azomethineylide would be formed by initial deprotonation of imine 13 
and successive anchorage to the thiourea catalyst V through hydrogen bonds as shown in Scheme 7. The 
addition of an external proton donor 2,2,2-trifluoroethanol (TFE) is believed to activate the imine moiety of 
compounds 13 and it would stabilize the transition state by the hydrogen bonds. 
Interestingly, Chen and co-workers reported the first asymmetric multicomponent version of this 1,3-
dipolar cycloaddition reaction using aldehydes 17, α-aminomalonates 18 and nitroalkenes 19, catalyzed by 
chiral thiourea-pyrrol structure VI. They obtained the corresponding pyrrolidine compounds 20 in good 





Based on the absolute configuration of final pyrrolidine adducts, the authors invoked the concerted 
1,3-dipolar cycloaddition shown in Figure 7. This process proceeds with the initial formation of an imine 21 
from the aldehyde 17 and α-aminomalonate 18. The formal azomethineylide 21 stabilized by a hydrogen 
bond, would react with the re-face of nitroalkenes 19 activated by the thiourea group of the catalyst VI 
through a double hydrogen bonding interaction, in a formal [3+2] cycloaddition reaction in an endo-attack 
(Figure 7). β-Phenyl group of compound 19 directed away from the catalyst, avoiding the steric hindrance, 
would allow the formation of the aforementioned double hydrogen-bonding interaction between the thiourea 






It is worth noting that in these three mechanisms (Schemes 6-8) the dipole is believed to be formed 
through deprotonation of the corresponding imine and subsequent activation by hydrogen bonds with the 
thiourea catalyst or with an additional proton donor, giving rise to the formal azomethineylide involved in 
the final step of the process. 
 
3. Synthesis of O-heterocyclic compounds 
3.1. Synthesis of 2-amino-4H-chromene derivatives 
Chromene scaffolds are a class of benzopyran derivatives commonly present in natural products and 
biologically active compounds. In particular, the synthesis of 2-amino-4H-chromenes has attracted much 
attention due to their pharmacological properties (HA14-1,27 MX58151,28 HFI-437,29 and inhibitor of MK-
230) (Figure 8). However, although many procedures have been reported for the racemic version of these 
compounds,31 asymmetric methodologies have been scarcely explored and they are of great interest.32 Some 
groups have performed pivotal contributions in this field using chiral thiourea catalysts as efficient tool for 








Wang and co-workers reported an interesting Mannich cyclization–tautomerization cascade procedure 
for the synthesis of 24 in high yields (81-94%) and good enantioselectivities (74-89%), promoted by catalyst 
 
 
(1S,2R)-VII. The method was also applicable to different protecting groups in the α-amidosulfone reagent 
22 (Scheme 9).33 
The same research group reported an interesting cascade approach for the obtainment of 2-amino-4H-
chromene derivatives 26 in high yields (90-96%) and high ee values (59-76%), using a new bifunctional 





In both mechanisms the thioureas VII and VIII are envisioned to play a bifunctional role activating at 
the same time the nucleophile and the electrophile of these reactions through the basic function and the 
thiourea moiety of both catalysts. 
Later, Yang, Liu and co-workers developed an interesting multicomponent reaction for the 
straightforward synthesis of similar functionalized chromenes 31 starting from salicylaldehyde 27, 






This protocol represents a straightforward approach for the construction of chiral highly functionalized 
2-amino-4H-chromenes 31 in good yields (41-92%) and with good enantioselectivities (58->99% ee) from 
simple starting materials. 
 
 
At the same time, Wang and co-workers developed a different multicomponent reaction using 
diketone 34, which allows the preparation of adducts 35a-d (Scheme 12). The authors use a terpene-derived 





Yang, Zhao and co-workers have reported the first synthesis of chiral naphthopyran derivatives38 (a 
class of 2-amino-4H-chromene derivatives) using an efficient bifunctional thiourea V to promote the 
addition–cyclization reaction of 2-naphthol 37 with α,α-dicyanoolefins 36 under mild conditions (Scheme 
13, a). The final adducts 38 were obtained in moderate to high yields (19-99%) and moderate to good 






Interestingly, the authors also explored the viability of the asymmetric three-component one-pot 
version, affording final products 38 with good results (67-93% yield and 33-65% ee), although slightly 
lower that employing the preformed malononitrile 36 (Scheme 13, b). The same group extended this 
reaction to a range of β,γ-unsaturated α-keto ester 40 instead of α,α-dicyanoolefins 36 (Schemes 14).40 In 
this case, the corresponding final chromene derivatives 41 were also obtained with good results (51-91% 





3.2. Synthesis of flavanones and chromanones 
Flavanone moiety is present in many biologically active products41 that exhibit anti-tumor and anti-
inflammatory properties, among others.42 However, methods which allow their asymmetric synthesis are 
very scarce in the literature.43 
Scheidt’s group has reported an enantioselective method for the synthesis of chromanones 43 starting 
from β-ketoester alkylidene substrates 42. Concerning the mechanism, the authors envisaged that 
bifunctional quinine-derived thiourea catalyst X would promote an intramolecular conjugate addition of a 
deprotonated phenol over the activated β-ketoesteralkylidene to deliver the desired flavanones (R1 = Ar) and 






It is worth noting that after the cyclization step, the 3-carboxylate group (X) can be removed by 
treatment with acid in toluene without affecting the integrity of the newly formed stereocenter at C2. This 
decarboxylation process allows formation of enantioenriched flavanones in high yields since the 3-carboxy 
flavanone products 44 are firstly formed as mixtures of cis and trans diastereomers. 
 
3.3. Synthesis of pyrans and their fused derivatives 
Pyran derivatives are a significant class of heterocyclic compounds which can exhibit biological and 
pharmacological activities (YCM1008A,45 melicobisquinolinone B,46 zhantosimuline,47,48 





Many of them could also be synthetic intermediate for the preparation of more complex scaffolds.51 
Consequently, the development of new synthetic approaches giving access to such compounds has attracted 
the interest of many research groups.52 
In this field, Zhao’s group has developed two interesting and straightforward methodologies using 
different nucleophiles for the chiral addition over β,γ-unsaturated α-ketoester 44. Malononitrile 2353 and 3-
oxo-3-phenylpropanenitrile 4654 were used in each case to afford the corresponding pyrans 45 and 47, 
respectively (Scheme 16). 
Other remarkable examples were developed by Wang and co-workers using (E)-3-
benzylidenechroman-4-one 4855 and 1,2-diones 5056 as key substrates to access the target compounds, 
pyranochromenes 49 and 3,4-dihydro-2H-pyrans 52, respectively (Scheme 17, a and b). 
Based on the experimental results, the first process is believed to proceed through an enantioselective 
cascade Michael-oxa-Michael-tautomerization sequence (Scheme 17, a) and the second one, through an 
enantioselective cascade Michael-enolation-cyclization process (Scheme 17, b). Both catalysts VII seem to 
play a bifunctional role in the activation of the reagents. In the second case, the catalyst VII would activate 
simultaneously the 1,2-cyclohexadione 50 and the β,γ-unsaturated α-keto ester 51 via its amine and thiourea 
functional groups, respectively, as represented in Scheme 18. After formation of Michael adducts 53, 
enolization and subsequent oxa-nucleophilic attack would complete the cyclization step. Finally, two 









The coumarin structural core is present in a large number of natural products and biologically active 
molecules.57 Many natural coumarin derivatives are precursors and synthetic intermediates in the 
construction of more complex structure and target compounds with interesting activities.58 We have 
 
 
considered these examples in this section because a pyran ring is generated in the course of the process,36 





In this field, Wang’s group developed an efficient enantioselective synthesis of coumarin analogues 
with high yields (90-98%) and excellent enantioselectivities (90-98%) using a simple amine-thiourea VIII 






Zhao, Cao and co-workers also developed a similar approach using β,γ-unsaturated α-keto esters and a 
different thiourea catalyst XI with a low catalytic charge (5 mol%) (Figure 10).60 Final chiral coumarin 
derivatives were synthesized in excellent yields (up to 99%) and excellent enantioselectivities (up to 96%) 













Kim and co-workers reported an appealing example of the use of thiourea catalyst XII, employing 4-
hydroxycoumarin 57 and β,γ-unsaturated α-keto esters 58, giving access to biologically valuable warfarin 









Final adducts 59 are obtained with good yields (60-96%) and high enantioselectivities (87-99%) under 
mild reaction conditions. Similar results were achieved by Yan’s group using Takemoto’s catalyst (V) and 
also a bifunctional mechanism is proposed to explain the dual role of the catalyst (Figure 11).62 
 
3.4. Synthesis of tetrahydrofurans 
The presence of tetrahydrofuran ring cores in natural products and biologically active agents,63 such as 
fosamprenavir (pro-drug of the protease inhibitor and antiretroviral drug amprenavir64),65 MK-28766 and 
caribenolide I67 (Figure 12), has promoted the development of numerous synthetic methods for their 
stereoselective preparation.68 Among these methods, cycloetherification allows the obtainment of 2-
substituted oxacyclic compounds in a straight way. Nevertheless, the enantioselective version of this 
reaction has not been intensively explored so far, and only few protocols have been developed. Some 





Matsubara’s group envisioned the possibility of using a bifunctional thiourea for the construction of 





Based on this idea, they developed a highly enantioselective catalytic cycloetherification method for 
the synthesis of 2-substituted tetrahydrofurans using ε-hydroxy-α,β-unsaturated ketones 60 and thiourea 
cinchona derivative IIIb, as efficient catalyst (Scheme 21). 
This method represents an interesting and straightforward synthetic approach for the preparation of 















































Additionally, Matsubara and co-workers have also applied the use of chiral (thio)ureas as catalysts for 
the efficient obtainment of a wide variety of heterocycles, such as 1,3-dioxolanes,70 tetrahydro-2H-pyran,71  





4. Synthesis of S-heterocyclic compounds 
4.1. Synthesis of benzothiopyrans (or thiochromanes) 
The presence of benzothio pyrans the structural core of more complex skeletons with biological 
activity, such as tertatolol,76 7-thia-DCK,77 among others,78 has encouraged the study of synthetic protocols, 
which allows their obtainment (Figure 15).79 
Thus, Wang and co-workers have developed different works for the preparation of benzothiopyrans. 
The authors have employed for this purpose 2-mercaptobenzaldehydes 62 with maleimides 63 (Scheme 
22),80 or with α,β-unsaturated oxazolidinones 65 (Scheme 23),81 and in both cases they envisioned the same 













More recently, the same group envisioned a Michael-Michael cascade reaction to obtain enantio-
enriched tiochromanes 69 through a dynamic kinetic resolution (DKR), as a new mode of activation of this 
kind of organocatalysts (Scheme 24).82 To explain the high enantioselection, the authors proposed an 
alternative pathway because low enantioselectivity was observed when they performed the reaction between 
thiophenol and trans-β-nitrostyrene under the same reaction conditions. In this case, based on the 
experimental results, they proposed a DKR-mediated Michael–retro-Michael–Michael–Michael cascade 








This interesting hypothesis was confirmed carrying out the reaction above described but starting from 







Organocatalysis is a research area in expansion, and (thio)urea organocatalysts in particular, have been 
intensively investigated in the last years. Some key (thio)urea-catalyzed synthesis of heterocyclic 
compounds have been disclosed and commented in this report. All these examples, together with many other 
interesting cases that have not been shown here, have strongly contributed to the development of 
Heterocyclic Chemistry. It is remarkable the importance of bifunctional thioureas as efficient catalysts in 
numerous processes of the abovementioned ones, since the dual role played by these molecules seems to be 
crucial for their success.83 The better knowledge about the mode of action of the (thio)ureas and the design 
of new molecules of this type will necessarily continue contributing in the near future to Heterocyclic 
Chemistry by the development of new efficient organocatalytic methods, which will allow the obtainment of 
many others and more complex heterocyclic structural cores. 
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